Fairvoy Private Wealth LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN

Fairvoy Private Wealth LLC acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,092 shares of the biopharmaceutical company’s stock, valued at approximately $844,000.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after purchasing an additional 26,884 shares in the last quarter. Dodge & Cox increased its position in shares of Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after buying an additional 45,513 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Regeneron Pharmaceuticals by 4.4% in the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after buying an additional 106,861 shares in the last quarter. Nuveen LLC raised its stake in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares during the period. Finally, Capital World Investors raised its stake in Regeneron Pharmaceuticals by 1.6% during the 3rd quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after buying an additional 32,348 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $620.14 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a market cap of $65.56 billion, a price-to-earnings ratio of 15.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.25. The stock’s 50-day moving average is $665.93 and its 200-day moving average is $729.12. Regeneron Pharmaceuticals, Inc. has a one year low of $514.79 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same quarter last year, the firm earned $8.22 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Insider Activity

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $900.00 to $700.00 in a research report on Monday, May 18th. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.